T Shea Osburn¹*, Victoria Acharya¹, Rhonda Keosheyan¹, Chloe Kupelian DO² and Nicole Webb¹

¹Division of Hospital Medicine, Valley Children’s Healthcare, USA ²Graduate Medical Education, Valley Children’s Healthcare, Madera, USA

*Corresponding Author:T Shea Osburn, Division of Hospital Medicine, Valley Children’s Healthcare, USA.

Received: May 30, 2022; Published: June 13, 2022

Abstract

Objective: Define the clinical characteristics, outcomes, and resource utilization patterns in pediatric patients with Multisystem Inflammatory Syndrome in Children (MIS-C) hospitalized at our center over the first year of the pandemic.

Methods: Retrospective case series of patients < 22 years with a discharge diagnosis of MIS-C between 5/1/20 and 4/30/21.Demographic, clinical, and outcome data was collected and analyzed. We then performed an analysis comparing resource utilization in the first six months of the time period to the second six months in the time period.

Results: Forty eight percent (38/81) of our population had a greater than 2g/dl drop in their hemoglobin during their hospitalization. 73% (59/81) had a 1g/dl or greater drop. Of the recommended labs, CRP (100%), D-dimer (98%), Ferritin (91%), ESR (87%) Procalcitonin (85%), Fibrinogen (85%) and BNP (85%) were most frequently abnormal. Triglycerides (17%), PT/PTT (50%) and LDH (59%) were least frequently abnormal. Between the two defined time periods, there was no statistically significant improvement in the number of lab draws obtained aside from lab draws for triglycerides (p = .049).

Conclusions: Our clinical findings are consistent with those already published in the literature. Outcomes were also positive, with no deaths in our cohort and 83% had no cardiac abnormalities six weeks after admission. Laboratory resource utilization was substantial and did not improve over the first year of MIS-C cases at our organization. Our patients with MIS-C did frequently experience significant drops in their hemoglobin. There is likely opportunity to refine the available guidelines for the management of MIS-C.

Keywords: Multisystem Inflammatory Syndrome in Children (MIS-C); Pediatric Hospital Medicine; Resource Utilization; Laboratory; SARS-CoV-2

References

1. HAN Archive - 00432 Health Alert Network (HAN).
2. Henderson Lauren A., et al. “American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2”. Arthritis and Rheumatology (Hoboken, N.J.)4 (2021): e13-29.
3. Payne, Amanda B., et al. “Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2”. JAMA Network Open6 (2021): e2116420.
4. Holm Mette., et al. “Multisystem Inflammatory Syndrome in Children Occurred in One of Four Thousand Children with Severe Acute Respiratory Syndrome Coronavirus 2”. Acta Paediatrica9 (2021): 2581-2583.
5. Noh Jungsik and Gaudenz Danuser. “Estimation of the Fraction of COVID-19 Infected People in U.S. States and Countries Worldwide”. PLOS ONE2 (2021): e0246772.
6. Webb Nicole E and T Shea Osburn. “Characteristics of Hospitalized Children Positive for SARS-CoV-2: Experience of a Large Center”. Hospital Pediatrics8 (2021): e133-141.
7. Kushner Lauren E., et al. “For COVID’ or ‘With COVID’: Classification of SARS-CoV-2 Hospitalizations in Children”. Hospital Pediatrics8 (2021): e151-156.
8. Schroeder Alan R., et al. “Safely Doing Less: A Missing Component of the Patient Safety Dialogue”. Pediatrics6 (2011): e1596-1597.
9. Coon Eric R., et al. “Overdiagnosis: How Our Compulsion for Diagnosis May Be Harming Children”. Pediatrics5 (2014): 1013-1023.
10. Størdal Ketil., et al. “Overtesting and Overtreatment-Statement from the European Academy of Paediatrics (EAP)”. European Journal of Pediatrics12 (2019): 1923-1927.
11. Defining Childhood Obesity | Overweight and Obesity | CDC.
12. Miller Allison D., et al. “Multisystem Inflammatory Syndrome in Children-United States, February 2020-July 2021”. Clinical Infectious Diseases (2021): ciab1007.
13. Davies, Patrick., et al. “One-Year Outcomes of Critical Care Patients Post-COVID-19 Multisystem Inflammatory Syndrome in Children”. JAMA Pediatrics12 (2021): 1281-1283.
14. Penner, Justin., et al. “6-Month Multidisciplinary Follow-up and Outcomes of Patients with Paediatric Inflammatory Multisystem Syndrome (PIMS-TS) at a UK Tertiary Paediatric Hospital: A Retrospective Cohort Study”. The Lancet. Child and Adolescent Health7 (2021): 473-482.
15. Molloy, Matthew., et al. “What Are We Missing in Our Search for MIS-C?” Hospital Pediatrics4 (2021): e66-69.
16. Matsubara, Daisuke., et al. “Longitudinal Assessment of Cardiac Outcomes of Multisystem Inflammatory Syndrome in Children Associated With COVID‐19 Infections”. Journal of the American Heart Association3 (2022): e023251.
17. Son Mary Beth F., et al. “Multisystem Inflammatory Syndrome in Children-Initial Therapy and Outcomes”. New England Journal of Medicine1 (2021): 23-34.
18. Ouldali Naïm., et al. “Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone with Course of Fever in Multisystem Inflammatory Syndrome in Children”. JAMA9 (2021): 855-864.
19. McArdle Andrew J., et al. “Treatment of Multisystem Inflammatory Syndrome in Children”. New England Journal of Medicine1 (2021): 11-22.
20. CDC COVID Data Tracker (2022).
21.  

Citation

Citation: T Shea Osburn.,et al. “Twelve Months of MIS-C: Does Increasing Experience Improve Resource Utilization?”. Acta Scientific Paediatrics 6.7 (2022): 06-16.

Copyright

Copyright: © 2022 T Shea Osburn.,et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.